FDA Approves New Intravenous Monkeypox Drug Treatment From PFIZER-Linked SIGA Technologies
Pfizer is apparently at it again, conveniently hitting another grand slam with another perfectly timed drug release for the latest viral outbreak sweeping the west – monkeypox.
After hitting it out of the park with their experimental mRNA Covid vaccine – typically what would be considered a once-in-a-lifetime development that’s cashing the company out to a tune of $1,000 per second – it seems like a long stretch that Pfizer would be involved in the ‘cure’ for the new outbreak, but hey, they apparently pulled it off.
Read More
